Hasil Pencarian - Nassim Anjidani

  • Menampilkan 1 - 9 hasil dari 9
Perbaiki Hasil
  1. 1
    Effects of age and gender on immunogenicity and reactogenicity of SpikoGen recombinant spike protein vaccine: a post-hoc analysis

    Effects of age and gender on immunogenicity and reactogenicity of SpikoGen recombinant spike protein vaccine: a post-hoc analysis oleh Nassim Anjidani, Ramin Shahpari, Hamidreza Kafi, Nikolai Petrovsky, Saghar Barati

    Diterbitkan 2024-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    A  Phase IV Study of the Safety and Efficacy of CinnoPar® in Iranian Patients with Osteoporosis

    A  Phase IV Study of the Safety and Efficacy of CinnoPar® in Iranian Patients with Osteoporosis oleh Ahmadreza Jamshidi, Farhad Gharibdoost, Sima Sedighi, Asghar Hajiabbasi, Amir-Hossein Salari, Alireza Khabbazi, Peyman Mottaghi, Ahmad Tahammoli Roudsari, Mehrdad Aghaei, Irandokht Shenavar Masooleh, Araz Sabzvari, Nassim Anjidani

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab: A case-series study

    Pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab: A case-series study oleh Maral Seyed Ahadi, Mohammad Ali Sahraian, Vahid Shaygannejad, Nassim Anjidani, Seyed Ehsan Mohammadiani Nejad, Nahid Beladi Moghadam, Hormoz Ayromlou, Gholam Ali Yousefi Pour, Sepideh Yazdanbakhsh, Mehrdad Jafari, Abdorreza Naser Moghadasi

    Diterbitkan 2021-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Zytux in Refractory Myasthenia Gravis: A Multicenter, Open-Labeled, Clinical Trial Study of Effectiveness and Safety of a Rituximab Biosimilar

    Zytux in Refractory Myasthenia Gravis: A Multicenter, Open-Labeled, Clinical Trial Study of Effectiveness and Safety of a Rituximab Biosimilar oleh Farzad Fatehi, Kamyar Moradi, Ali Asghar Okhovat, Ali Asghar Okhovat, Ghazaleh Shojatalab, Behnaz Sedighi, Reza Boostani, Payam Sarraf, Payam Sarraf, Bahram Haghi Ashtiani, Majid Ghasemi, Soussan Moussavi, Nassim Anjidani, Shahriar Nafissi

    Diterbitkan 2021-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial

    Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, d... oleh Ahmadreza Jamshidi, Mahdi Vojdanian, Mohsen Soroush, Mahmoud Akbarian, Mehrdad Aghaei, Asghar Hajiabbasi, Zahra Mirfeizi, Alireza Khabbazi, Gholamhosein Alishiri, Anousheh Haghighi, Ahmad Salimzadeh, Hadi Karimzadeh, Fatemeh Shirani, Mohammad Reza Hatef Fard, MohammadAli Nazarinia, Soosan Soroosh, Nassim Anjidani, Farhad Gharibdoost

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

    Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency cl... oleh Abolghasem Allahyari, Ali Ehsanpour, Nafiseh Ansarinejad, Valiollah Mehrzad, Behjat Kalantari, Jahangir Raafat, Mojtaba Ghadiany, Farhad Shahi, Behrooz Gharib, Vahid Moazed, Adnan Khosravi, Mir Hossein Mirpour, Sina Salari, Seyedmohammadreza Mortazavizadeh, Amirabbas Nekoyi, Mohsen Khani, Alireza Sadeghi, Sirus Gharib, Alireza Bary, Mehrzad Mirzania, Shirin Haghighat, Seyed Mohsen Razavi, Seyed Amir Hossein Emami, Mehran Hosseinzadeh, Mahdi Mirbolouk, Sanambar Sadighi, Abdolali Shahrasbi, Ali Esfahani, Masoumeh Gity, Nassim Anjidani, Hamidreza Kafi, Safa Najafi

    Diterbitkan 2022-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

    Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, eq... oleh Abolghasem Allahyari, Ali Ehsanpour, Behrouz Najafi, Nafseh Ansarinejad, Valiollah Mehrzad, Behjat Kalantari, Jahangir Raafat, Mojtaba Ghadiany, Farhad Shahi, Behrooz Gharib, Vahid Moazed, Adnan Khosravi, Mir Hossein Mirpour, Sina Salari, Seyedmohammadreza Mortazavizadeh, Amirabbas Nekoyi, Mohsen Khani, Alireza Sadeghi, Sirus Gharib, Alireza Bary, Mehrzad Mirzania, Shirin Haghighat, Seyed Mohsen Razavi, Seyed Amir Hossein Emami, Mehran Hosseinzadeh, Mahdi Mirbolouk, Sanambar Sadighi, Abdolali Shahrasbi, Ali Esfahani, Masoumeh Gity, Nassim Anjidani, Hamidreza Kaf, Safa Najaf

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    A Post-Marketing Surveillance Study to Evaluate the Safety Profile of AlvotereⓇ (Docetaxel) in Iranian Patients Diagnosed with Different Types of Cancers Receiving Chemotherapy

    A Post-Marketing Surveillance Study to Evaluate the Safety Profile of AlvotereⓇ (Docetaxel) in Iranian Patients Diagnosed with Different Types of Cancers Receiving Chemotherapy oleh Farhad Shahi, Associate Professor, Farahnaz Vafaeezadeh, Post doctoral fellowship, Nafiseh Ansarinejad, Associate Professor, Alireza Ahmadi, Post doctoral fellowship, Ali Shahriari-Ahmadi, Associate Professor, Alireza Ghazizadeh, Associate Professor, Hassanali Vahedian Ardakani, Associate Professor, Mohammad Reza Ravanbod, Associate Professor, Sharareh Seifi, Associate Professor, Mohammad Foratyazdi, Associate Professor, Seyed Asadollah Mousavi, Associate Professor, Mansour Rajabi Vahid, Associate Professor, Hossein Rahimi, Associate Professor, Mohammad Seghatoleslami, Post doctoral fellowship, Seyed Mohsen Razavi, Associate Professor, Amir Houshang Pourkhani, Associate Professor, Davoud Babakhani, Post doctoral fellowship, Nassim Anjidani, Pharm. D.

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Post-Marketing Surveillance of a generic Oxaliplatin (AlvoxalⓇ) in Iranian Patients with Cancer

    Post-Marketing Surveillance of a generic Oxaliplatin (AlvoxalⓇ) in Iranian Patients with Cancer oleh Farhad Shahi, Mojtaba Gorji, Assistant Professor of Pediatric Oncology, Mehrdad Payandeh, Assistant Professor of Hematology & Oncology, Hamid Rezvani, Associate Professor of Hematology & Oncology, Mohammad Vaezi, Associate Professor of Hematology & Oncology, Sharareh Seifi, Assistant Professor of Hematology & Oncology, Alireza Baari, Post doctoral fellowship, Reza Khalili-Dizaji, Post doctoral fellowship, Seyed Mehdi Hashemi, Associate Professor of Hematology & Oncology, Saeid Salimi, post doctoral fellowship, Hosein Kamranzadeh, Associate Professor of Hematology & Oncology, Babak Shazad, Post doctoral fellowship, Sina Salari, Associate Professor of Hematology & Oncology, Davoud Oulad Dameshghi, Assistant Professor of Hematology & Oncology, Mehdi Sarkheil, Post doctoral fellowship, Mehrzad Mirzania, Associate Professor of Hematology & Oncology, Nassim Anjidani, Pharm. D.

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: